The FIND-Chip microfluidic platform identifies viable oocytes in follicular fluid that manual laboratory screening typically misses, potentially increasing the number of eggs available for each IVF cycle. Clinical validation showed the automated system consistently recovered additional oocytes beyond what trained embryologists detected through conventional visual inspection methods. This technological advancement addresses a critical bottleneck in assisted reproduction where oocyte quantity directly correlates with treatment success rates. For women with diminished ovarian reserve or those undergoing single-cycle retrievals, even one additional viable egg can meaningfully improve pregnancy odds. The automation also standardizes a process that relies heavily on technician skill and fatigue levels, reducing human error during the time-sensitive post-retrieval window. While the device represents meaningful progress in reproductive technology, its impact will depend on integration costs and whether the additional eggs translate to higher live birth rates rather than just increased embryo numbers. The innovation exemplifies how microfluidics can enhance precision in medical procedures where manual methods reach physiological limits.